Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 4 opinions in the last 12 months.
Knight Therapeutics (GUD-T) has garnered attention from several analysts, highlighting its potential as a solid long-term hold, particularly on pullbacks. Despite recent volatility in Latin American markets, experts believe the company’s strong cash position and capital discipline will allow it to leverage acquisitions effectively. Some reviews emphasize the hidden gem status of Knight Therapeutics, with a strong topline growth and margin expansion potential driven by its acquisition strategy. However, while the stock is up significantly year-to-date, recent earnings showed mixed results, with some contributors noting that challenges remain despite a promising net cash position. Overall, analyses suggest a cautious optimism, advocating for patience as the company works towards improving margins over time.
A hidden gem. Low liquidity, but has good topline growth, strong margin expansion potential and the CEO has a great track record from Paladin Labs. It buys existing drug platforms, and can now leverage that platform to introduce new drug therapies. Huge net cash and keep buying back shares.
(Analysts’ price target is $7.60)The stock is acting better, and is up 15% YTD. It has been a while since it saw $6. EPS was -4c vs expectations of (nil). Revenue was $86.6M, beating estimates of $83.1M. EBITDA of $13.58M missed estimates of this $14.47M. Guidance was largely maintained. Revenue rose 4.9%, with margins a bit higher than estimates. Net cash is about $90M. Still not much excitement here. Some recent partnerships look more interesting than the quarterly results. It is good to see the sales gain, but we would not yet call this a dramatic turn.
Unlock Premium - Try 5i Free
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research. Trades at a cheap valuation. Investors’ patience has run out. Recent acquisition gave it a new life. Current environment can be favorable. Unlock Premium - Try 5i Free
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Although the stock has not moved, the basic thesis has not changed. There is some weakness in South America which has impacted their acquisition. With no dividend, there is an opportunity cost to the stock, but outlook remains intact. Unlock Premium - Try 5i Free
Knight Therapeutics is a Canadian stock, trading under the symbol GUD-T on the Toronto Stock Exchange (GUD-CT). It is usually referred to as TSX:GUD or GUD-T
In the last year, 3 stock analysts published opinions about GUD-T. 2 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Knight Therapeutics.
Knight Therapeutics was recommended as a Top Pick by on . Read the latest stock experts ratings for Knight Therapeutics.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
3 stock analysts on Stockchase covered Knight Therapeutics In the last year. It is a trending stock that is worth watching.
On 2025-04-25, Knight Therapeutics (GUD-T) stock closed at a price of $5.9.
Solid hold over the longer term, need patience. Accumulate on any pullback. Volatility of Latin American markets is not helping, so watch that. Understands how to monetize recent acquisition.